- Home
- TARS vs RHI Comparison
TARS vs RHI Comparison
Compare TARS & RHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TARS | RHI |
|---|---|---|
| Founded | 2016 | 1948 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Professional Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.8B |
| IPO Year | 2020 | 1994 |
Fundamental Metrics
Financial Performance| Metric | TARS | RHI |
|---|---|---|
| Price | $61.92 | $32.52 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 6 | 7 |
| Target Price | ★ $89.00 | $30.33 |
| AVG Volume (30 Days) | 529.2K | ★ 2.3M |
| Earning Date | 05-06-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 8.68% |
| EPS Growth | ★ 48.21 | N/A |
| EPS | N/A | ★ 0.14 |
| Revenue | $451,360,000.00 | ★ $5,378,506,000.00 |
| Revenue This Year | $56.43 | $1.27 |
| Revenue Next Year | $30.19 | $5.95 |
| P/E Ratio | ★ N/A | $214.93 |
| Revenue Growth | ★ 146.71 | N/A |
| 52 Week Low | $38.51 | $21.83 |
| 52 Week High | $85.25 | $43.82 |
Technical Indicators
Market Signals| Indicator | TARS | RHI |
|---|---|---|
| Relative Strength Index (RSI) | 47.11 | 62.38 |
| Support Level | $60.95 | $25.93 |
| Resistance Level | $66.36 | $33.26 |
| Average True Range (ATR) | 2.83 | 1.42 |
| MACD | 0.40 | -0.18 |
| Stochastic Oscillator | 28.21 | 84.87 |
Price Performance
Historical ComparisonAbout TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
About RHI Robert Half Inc.
Robert Half Inc was founded in 1948, Robert Half provides temporary, permanent, and outcome-based staffing for both in-person and remote positions in the finance and accounting, technology, legal, marketing, and administrative fields. Its subsidiary consulting arm, Protiviti, specializes in technology, risk, auditing, and compliance matters. The firm generates its sales inside the U.S. and is one of the specialized firms in the fragmented U.S. staffing industry.